most common type of cryptocurrency searches

Macron rejected our proposal and appointed one of his allies as Prime Minister. We will not enter the government, and Macron chooses to continue his policy.Two States in the United States sued Glock, a gun manufacturer, for ignoring the design flaw that "pistols can easily become machine guns". On the 12th, the prosecutors in New Jersey and Minnesota respectively sued Glock, an Austrian weapons manufacturer, accusing the pistol manufactured by them of design defects and being easily converted into illegal machine guns. According to the complaint, Glock knew this situation for a long time, and continued to sell this pistol to the United States and profit from it, which promoted the proliferation of gun violence in the United States. (Xinhua News Agency)Shenzhen sub-district strong monsoon blue warning signal, Shenzhen Meteorological Observatory issued strong monsoon blue warning signals for Luohu District, Yantian District, Dapeng New District, Dapeng Bay and Daya Bay at 21: 20 on December 13, 2024. Due to the influence of cold air, the maximum gust in the above areas is expected to be 7-8, and the signal may last until the morning of the 15th. Please implement various wind protection measures.

The Bank of Italy said that the economy may only grow by 0.5% this year, and the Bank of Italy said in a statement on Friday that the gross domestic product (GDP) will increase by 0.5% in 2024. If seasonal and calendar effects are not taken into account, this figure will increase to 0.7%, but it is lower than the government's estimate of 1% in the budget. In addition, GDP growth is expected to be 0.8% in 2025 and 1.1% in 2026. It is estimated that the unified average inflation rate in the EU will be 1.1% in 2024, which is the same as the estimated value in October, 1.5% in 2025 and 1.6% in 2025.Kang Enbei: Amikacin Sulfate Injection is planned to win the bid for the tenth batch of national centralized drug purchase. On December 12th, Kang Enbei and its wholly-owned subsidiary Jinhua Kang Enbei participated in the bidding for the tenth batch of national centralized drug purchase organized by the National Joint Procurement Office for Centralized Drug Purchase and Use. After the bid opening and bid evaluation by the Joint Procurement Office, the company's product Amikacin Sulfate Injection plans to win the bid for this centralized procurement, and the supply provinces have been selected according to the market potential of each province. The successful results will be officially released after being publicized by the Joint Procurement Office. Amikacin sulfate injection is suitable for the treatment of serious infections caused by Pseudomonas aeruginosa, other Pseudomonas, Escherichia coli and other sensitive gram-negative bacilli and Staphylococcus (methicillin-sensitive strains). Compared with the original price, the price of the product to be selected this time has dropped to a certain extent.Musk received an ultimatum from the SEC or faced multiple accusations, and the long-term confrontation between the US SEC and Musk escalated again. On December 12th, local time, Alex spiro, a lawyer of Musk, wrote to Gary Gensler, the outgoing chairman of the SEC, accusing the agency of launching an "ulterior motive action" against Musk, and revealed that the SEC had restarted the investigation of Neuralink, a brain-computer interface company owned by Musk. According to the contents of the letter, the SEC asked Musk to accept the settlement agreement within 48 hours and pay the fine, otherwise he would face "multiple accusations". These allegations are related to Musk's stock investment behavior before the acquisition of Twitter (now "X") in 2022, involving trading time and the legality of information disclosure. It was mentioned in the letter that the accusation originated from an investigation that lasted for several years, and the SEC recently issued a subpoena to Musk's lawyer, asking him to provide testimony. Alex spiro said that he had explicitly refused to cooperate and accused the agency of "political motives". Musk also posted a letter from his lawyer to Gary Gensler on social media, with the text "Gary, how could you do this to me" and a crying emoji. Alex spiro also asked in his letter who was directing the SEC's actions. Alex spiro emphasized that the SEC's "harassment" of Musk and its affiliates for six years has deviated from the original intention of seeking the truth and become an improper pressure. At present, the SEC has not commented on this. In addition, the letter said that the SEC also restarted the investigation of Neuralink, a brain-computer interface company owned by Musk. This autumn, the animal protection organization "Committee of Responsible Medical Doctors" and four US congressmen asked the SEC to investigate Neuralink, accusing it of securities fraud through misleading propaganda. (Securities Times)

Kexing launched the world's first phase III clinical study of bivalent inactivated enterovirus vaccine. On December 13th, the first volunteer was enrolled in the phase III clinical study of bivalent inactivated enterovirus vaccine developed by Beijing Kexing Biological Products Co., Ltd., a subsidiary of Kexing Holding Biotechnology Co., Ltd. (hereinafter referred to as "Kexing"). The vaccine is used to prevent hand, foot and mouth disease caused by enterovirus 71 (EV71) and coxsackie virus 16 (CA16). A multicenter, randomized, double-blind, controlled study design was adopted in this phase III clinical study to evaluate the protective efficacy, safety and immunogenicity of the vaccine in children aged 6-71 months.Haitian Weiye, a soy sauce manufacturer, is reported to have hired a bank to handle the listing in Hong Kong. According to informed sources, Haitian Weiye, one of the largest condiment manufacturers in China, has hired CICC, Goldman Sachs and Morgan Stanley to handle the second listing in Hong Kong, which may raise at least $1.5 billion. According to people familiar with the matter, Haitian plans to submit a preliminary prospectus to the Hong Kong Stock Exchange as early as January.Kexing launched the world's first phase III clinical study of bivalent inactivated enterovirus vaccine. On December 13th, the first volunteer was enrolled in the phase III clinical study of bivalent inactivated enterovirus vaccine developed by Beijing Kexing Biological Products Co., Ltd., a subsidiary of Kexing Holding Biotechnology Co., Ltd. (hereinafter referred to as "Kexing"). The vaccine is used to prevent hand, foot and mouth disease caused by enterovirus 71 (EV71) and coxsackie virus 16 (CA16). A multicenter, randomized, double-blind, controlled study design was adopted in this phase III clinical study to evaluate the protective efficacy, safety and immunogenicity of the vaccine in children aged 6-71 months.